| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 25.47% | Goldman Sachs | $117 → $144 | Maintains | Buy |
| 12/08/2022 | 23.73% | Credit Suisse | $59 → $142 | Maintains | Outperform |
| 12/08/2022 | 57.71% | BTIG | $74 → $181 | Maintains | Buy |
| 12/08/2022 | 8.91% | Oppenheimer | $61 → $125 | Maintains | Outperform |
| 12/08/2022 | -3.28% | RBC Capital | $66 → $111 | Maintains | Outperform |
| 11/01/2022 | -52.08% | Stifel | $50 → $55 | Maintains | Buy |
| 10/04/2022 | -43.36% | Oppenheimer | $50 → $65 | Maintains | Outperform |
| 10/04/2022 | -42.49% | RBC Capital | $61 → $66 | Maintains | Outperform |
| 10/03/2022 | -35.52% | BTIG | $62 → $74 | Maintains | Buy |
| 08/29/2022 | -41.62% | Piper Sandler | $53 → $67 | Maintains | Overweight |
| 08/29/2022 | -38.14% | Wells Fargo | $51 → $71 | Maintains | Overweight |
| 08/12/2022 | -48.59% | Credit Suisse | $52 → $59 | Maintains | Outperform |
| 08/12/2022 | -47.72% | SVB Leerink | $55 → $60 | Maintains | Outperform |
| 07/20/2022 | -55.56% | Goldman Sachs | → $51 | Initiates Coverage On | → Buy |
| 06/10/2022 | -53.82% | Piper Sandler | → $53 | Initiates Coverage On | → Overweight |
| 05/13/2022 | -60.79% | RBC Capital | $46 → $45 | Maintains | Outperform |
| 05/13/2022 | -55.56% | Wells Fargo | $53 → $51 | Maintains | Overweight |
| 03/10/2022 | -54.69% | Credit Suisse | $50 → $52 | Maintains | Outperform |
| 03/10/2022 | -53.82% | Wells Fargo | $42 → $53 | Maintains | Overweight |
| 03/10/2022 | -52.08% | SVB Leerink | $47 → $55 | Maintains | Outperform |
| 02/11/2022 | -45.98% | BTIG | → $62 | Initiates Coverage On | → Buy |
| 12/13/2021 | -59.92% | RBC Capital | → $46 | Initiates Coverage On | → Outperform |
| 12/08/2021 | -63.41% | Wells Fargo | → $42 | Initiates Coverage On | → Overweight |
| 12/08/2021 | -56.43% | Oppenheimer | $35 → $50 | Upgrades | Perform → Outperform |
| 12/08/2021 | -59.05% | SVB Leerink | $43 → $47 | Maintains | Outperform |
| 11/15/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 11/15/2021 | -62.53% | SVB Leerink | $34 → $43 | Maintains | Outperform |
| 10/05/2021 | -69.5% | Oppenheimer | → $35 | Initiates Coverage On | → Outperform |
| 04/06/2021 | -65.15% | Guggenheim | → $40 | Initiates Coverage On | → Buy |
| 04/06/2021 | -78.22% | Stifel | → $25 | Initiates Coverage On | → Buy |
| 04/06/2021 | -70.38% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 04/06/2021 | -73.86% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
What is the target price for Prometheus Biosciences (RXDX)?
The latest price target for Prometheus Biosciences (NASDAQ: RXDX) was reported by Goldman Sachs on January 31, 2023. The analyst firm set a price target for $144.00 expecting RXDX to rise to within 12 months (a possible 25.47% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prometheus Biosciences (RXDX)?
The latest analyst rating for Prometheus Biosciences (NASDAQ: RXDX) was provided by Goldman Sachs, and Prometheus Biosciences maintained their buy rating.
When is the next analyst rating going to be posted or updated for Prometheus Biosciences (RXDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prometheus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prometheus Biosciences was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
Is the Analyst Rating Prometheus Biosciences (RXDX) correct?
While ratings are subjective and will change, the latest Prometheus Biosciences (RXDX) rating was a maintained with a price target of $117.00 to $144.00. The current price Prometheus Biosciences (RXDX) is trading at is $114.77, which is out of the analyst's predicted range.